Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Antonino Musolino, Filippo Montemurro, Daniela Rubino et al.|Journal of Clinical Oncology|2017

Cited by 0